Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement